Pharmacokinetics of tobramycin and gentamicin in abusers of intravenous drugs

C. H. King, R. J. Creger, J. J. Ellner

Research output: Contribution to journalArticle

Abstract

The kinetics of aminoglycoside elimination were determined in 18 hospitalized narcotics abusers receiving gentamicin or tobramycin for treatment of severe infection. Rapid aminoglycoside elimination (requiring doses of > 5 mg/kg per day to maintain adequate drug levels) was noted in 12 of the 18 patients (18 of 27 clearance studies). Patients found to have rapid elimination were younger (P <0.01) and had larger drug distribution volumes (P <0.005), greater measured creatinine clearances (P <0.05), and lower creatinine levels in serum (P <0.001) than those with normal elimination. Nevertheless, by regression analysis, age, creatinine levels in serum, creatinine clearances, and drug distribution volumes proved to be unreliable predictors of individual aminoglycoside clearance. Measured drug half-life in serum appeared to be the only reliable predictor of drug clearance (r = 0.93). Patients with rapid drug elimination had aminoglycoside clearances 16 to 43% greater than measured creatinine clearances, suggesting an extraglomerular route of drug elimination. We conclude that in drug abuse patients a significant and clinically unpredictable interpatient variation occurs in aminoglycoside elimination and that accurate serum kinetics are needed to determine therapeutic dosing. In addicts younger than 35 years, with a creatinine level of <1.0 mg/100 ml in serum, the risk of inadequate therapy is high if standard dosing guidelines are followed. For this group, initial dosing of 8 mg/kg per day, with a drug half-life determination on the first dose, is recommended. Pharmacokinetic analysis is critical for all drug abusers treated with aminoglycosides for serious infection.

Original languageEnglish (US)
Pages (from-to)285-290
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume27
Issue number3
StatePublished - 1985
Externally publishedYes

Fingerprint

Tobramycin
Drug Users
Gentamicins
Aminoglycosides
Pharmacokinetics
Creatinine
Pharmaceutical Preparations
Serum
Half-Life
Narcotics
Infection
Substance-Related Disorders
Therapeutics
Regression Analysis
Guidelines

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Pharmacokinetics of tobramycin and gentamicin in abusers of intravenous drugs. / King, C. H.; Creger, R. J.; Ellner, J. J.

In: Antimicrobial Agents and Chemotherapy, Vol. 27, No. 3, 1985, p. 285-290.

Research output: Contribution to journalArticle

King, C. H. ; Creger, R. J. ; Ellner, J. J. / Pharmacokinetics of tobramycin and gentamicin in abusers of intravenous drugs. In: Antimicrobial Agents and Chemotherapy. 1985 ; Vol. 27, No. 3. pp. 285-290.
@article{8822c2876c61417f999c30488b8ddee7,
title = "Pharmacokinetics of tobramycin and gentamicin in abusers of intravenous drugs",
abstract = "The kinetics of aminoglycoside elimination were determined in 18 hospitalized narcotics abusers receiving gentamicin or tobramycin for treatment of severe infection. Rapid aminoglycoside elimination (requiring doses of > 5 mg/kg per day to maintain adequate drug levels) was noted in 12 of the 18 patients (18 of 27 clearance studies). Patients found to have rapid elimination were younger (P <0.01) and had larger drug distribution volumes (P <0.005), greater measured creatinine clearances (P <0.05), and lower creatinine levels in serum (P <0.001) than those with normal elimination. Nevertheless, by regression analysis, age, creatinine levels in serum, creatinine clearances, and drug distribution volumes proved to be unreliable predictors of individual aminoglycoside clearance. Measured drug half-life in serum appeared to be the only reliable predictor of drug clearance (r = 0.93). Patients with rapid drug elimination had aminoglycoside clearances 16 to 43{\%} greater than measured creatinine clearances, suggesting an extraglomerular route of drug elimination. We conclude that in drug abuse patients a significant and clinically unpredictable interpatient variation occurs in aminoglycoside elimination and that accurate serum kinetics are needed to determine therapeutic dosing. In addicts younger than 35 years, with a creatinine level of <1.0 mg/100 ml in serum, the risk of inadequate therapy is high if standard dosing guidelines are followed. For this group, initial dosing of 8 mg/kg per day, with a drug half-life determination on the first dose, is recommended. Pharmacokinetic analysis is critical for all drug abusers treated with aminoglycosides for serious infection.",
author = "King, {C. H.} and Creger, {R. J.} and Ellner, {J. J.}",
year = "1985",
language = "English (US)",
volume = "27",
pages = "285--290",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - Pharmacokinetics of tobramycin and gentamicin in abusers of intravenous drugs

AU - King, C. H.

AU - Creger, R. J.

AU - Ellner, J. J.

PY - 1985

Y1 - 1985

N2 - The kinetics of aminoglycoside elimination were determined in 18 hospitalized narcotics abusers receiving gentamicin or tobramycin for treatment of severe infection. Rapid aminoglycoside elimination (requiring doses of > 5 mg/kg per day to maintain adequate drug levels) was noted in 12 of the 18 patients (18 of 27 clearance studies). Patients found to have rapid elimination were younger (P <0.01) and had larger drug distribution volumes (P <0.005), greater measured creatinine clearances (P <0.05), and lower creatinine levels in serum (P <0.001) than those with normal elimination. Nevertheless, by regression analysis, age, creatinine levels in serum, creatinine clearances, and drug distribution volumes proved to be unreliable predictors of individual aminoglycoside clearance. Measured drug half-life in serum appeared to be the only reliable predictor of drug clearance (r = 0.93). Patients with rapid drug elimination had aminoglycoside clearances 16 to 43% greater than measured creatinine clearances, suggesting an extraglomerular route of drug elimination. We conclude that in drug abuse patients a significant and clinically unpredictable interpatient variation occurs in aminoglycoside elimination and that accurate serum kinetics are needed to determine therapeutic dosing. In addicts younger than 35 years, with a creatinine level of <1.0 mg/100 ml in serum, the risk of inadequate therapy is high if standard dosing guidelines are followed. For this group, initial dosing of 8 mg/kg per day, with a drug half-life determination on the first dose, is recommended. Pharmacokinetic analysis is critical for all drug abusers treated with aminoglycosides for serious infection.

AB - The kinetics of aminoglycoside elimination were determined in 18 hospitalized narcotics abusers receiving gentamicin or tobramycin for treatment of severe infection. Rapid aminoglycoside elimination (requiring doses of > 5 mg/kg per day to maintain adequate drug levels) was noted in 12 of the 18 patients (18 of 27 clearance studies). Patients found to have rapid elimination were younger (P <0.01) and had larger drug distribution volumes (P <0.005), greater measured creatinine clearances (P <0.05), and lower creatinine levels in serum (P <0.001) than those with normal elimination. Nevertheless, by regression analysis, age, creatinine levels in serum, creatinine clearances, and drug distribution volumes proved to be unreliable predictors of individual aminoglycoside clearance. Measured drug half-life in serum appeared to be the only reliable predictor of drug clearance (r = 0.93). Patients with rapid drug elimination had aminoglycoside clearances 16 to 43% greater than measured creatinine clearances, suggesting an extraglomerular route of drug elimination. We conclude that in drug abuse patients a significant and clinically unpredictable interpatient variation occurs in aminoglycoside elimination and that accurate serum kinetics are needed to determine therapeutic dosing. In addicts younger than 35 years, with a creatinine level of <1.0 mg/100 ml in serum, the risk of inadequate therapy is high if standard dosing guidelines are followed. For this group, initial dosing of 8 mg/kg per day, with a drug half-life determination on the first dose, is recommended. Pharmacokinetic analysis is critical for all drug abusers treated with aminoglycosides for serious infection.

UR - http://www.scopus.com/inward/record.url?scp=0021917047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021917047&partnerID=8YFLogxK

M3 - Article

C2 - 3994344

AN - SCOPUS:0021917047

VL - 27

SP - 285

EP - 290

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 3

ER -